NCT04635631View on ClinicalTrials.gov

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

August 8, 2021

Study Completion Date

December 14, 2021

Conditions
Neoplasms
Interventions
DRUG

talazoparib

Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.

Trial Locations (2)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

130000

Jilin Cancer Hospital, Changchun

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04635631 - STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS | Biotech Hunter | Biotech Hunter